

DAFTAR PUSTAKA

- Adiwinata, R., Rasidi, J., & Marpaung, M., 2018, Profil Klinis dan Evaluasi Pengobatan Pasien Rifampicin-Resistant dan Multidrug-Resistant Tuberculosis di RSUD Dr. Kanujoso Djatiwibowo Balikpapan, *Jurnal Respirasi Indonesia*, 38, 135–142.
- Agustina, R., Maulida, R., & Yovsyah, 2018, Faktor-Faktor yang Berhubungan dengan Kesuksesan Kesembuhan dari Pengobatan Regimen Pendek (Short Treatment Regiment) pada Pasien Tuberkulosis Resistensi Obat di Indonesia Tahun 2017, *Jurnal Epidemiologi Kesehatan Indonesia*, 2(2).
- Aminah, N. S., & Djuwita, R., 2021, Trend dan Faktor yang Berhubungan dengan Keberhasilan Pengobatan Pasien TB MDR Paduan Jangka Pendek di Indonesia 2017–2019, *Pro Health Jurnal Ilmiah Kesehatan*, 3(1), 109–117.
- Anisah, A., Sumekar, D. W., & Budiarti, E., 2021, Demografi dan Komorbid dengan Kejadian Tuberkulosis Resisten Obat, *Jurnal Ilmiah Kesehatan Sandi Husada*, 10(2), Desember.
- Arianti, A. R., Syamsudin, R., Sumarny, R., & Syamsi, L. N., 2024, Risk Factor Analysis of Drug-Resistant Tuberculosis in Tuberculosis Patients at Level II Health Facilities in Depok City, West Java Period March 2022–May 2023, *Daengku: Journal of Humanities and Social Sciences Innovation*, 4(1).
- Aviana, F., Jati, S. P., & Budiayanti, R. T., 2021, Systematic Review Pelaksanaan Programmatic Management of Drug-Resistant Tuberculosis pada Pasien Tuberkulosis Resistan Obat, *Jurnal Kesehatan Masyarakat*, 9(2), 215–222.
- Azzahra, U.F., 2023, Profil Klinis dan Evaluasi Rasionalitas Penggunaan Obat Anti Tuberkulosis pada Pasien Tuberkulosis Resistan Obat di RST Wijayakusuma Purwokerto, *Skripsi*, Fakultas Farmasi Universitas Gadjah Mada.
- Azzouz, A., & Preuss, C.V., 2025, *Linezolid*, StatPearls Publishing, Treasure Island.
- Baluku, J.B., Nabwana, M., Nalunjogi, J., Muttamba, W., Mubangizi, I., Nakiyingi, L., Ssengooba, W., Olum, R., Bongomin, F., Andia-Biraro, I., & Worodria, W., 2022, Cardiovascular Risk Factors Among People with Drug-Resistant Tuberculosis in Uganda, *BMC Cardiovascular Disorders*, 22(1), 464.
- Baggio, D., & Ananda-Rajah, M.R., 2021, Fluoroquinolone Antibiotics and Adverse Events, *Australian Prescriber*, 44(5).

- Baya, B., Achenbach, C.J., Kone, B., Toloba, Y., Dabita, D.K., Diarra, B., Goita, D., Diabaté, S., Maiga, M., Soumare, D., Ouattara, K., Kanoute, T., Berthe, G., Kamia, Y. M., Sarro, Y. D. S., Sanogo, M., Togo, A. C. G., Dembele, B. P. P., Coulibaly N., Kone, A., Akanbi, M., Belson, M., Dao, S., Orsega, S., Siddiqui, S., Doumbia, S., Murphy, R. L., & Diallo, S., Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali, *Int J Infect Dis*, 81, 149-155.
- Bayan, U., Prihanto, E., & Anwar, M., 2022, Karakteristik Pasien Tuberkulosis Resistan Obat di RSUD Dr. H. Chasan Boesoirie, *Kieraha Medical Journal*, 4(1).
- Bijawati, E., Amansyah, M., & Nurbiah, 2018, Faktor Risiko Pengobatan Pasien Multidrug Resistance Tuberculosis (MDR-TB) di RSUD Labuang Baji Kota Makassar tahun 2017, *Jurnal Nasional Ilmu Kesehatan (JNIK)*, 1(1).
- Brandariz-Núñez, D., Hernández-Corredoira, V., Guarco-Prades, E., & García-Navarro, B., 2019, Optic Neuropathy Associated with Linezolid: Systematic Review of Cases, *Farmacia Hospitalaria*, 43(2), 61–65.
- Brode, S.K., Dwirow, R., Kunimoto, D., Menzies, D., Khan, F.A., 2022, Chapter 8: Drug-resistant tuberculosis, *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*, 6(sup1), 109–128.
- Campbell, J. R., Nsengiyumva, P., Chiang, L. Y., Jamieson, F., Khadawardi, H., Mah, H. K., Oxlade, O., Rasberry, H., Rea, E., Romanowski, K., Sabur, N. F., Sander, B., Uppal, A., Johnston, J. C., Schwartzman, K., & Brode, S. K., 2022, Costs of Tuberculosis at 3 Treatment Centers, Canada, 2010–2016, *Emerging Infectious Diseases*, 28(9), 1814–1823.
- Chandra, A., Kumar, R., Kant, S., Parthasarathy, R., & Krishnan, A., 2020, Direct and indirect patient costs of tuberculosis care in India, *Tropical Medicine & International Health*, 25(6), 803–812.
- Chasanah, K.F., Trinawati, I., & Istiono, W., 2022, Risk Factor Identification of Multi-Drug Resistant Tuberculosis in Special Region Of Yogyakarta, *Review of Primary Care Practice and Education*, 5(1), 20–24.
- Damtie, D., Woldeyohannes, D., & Tebeje, B., 2014, Review on Molecular Mechanism of First Line Antibiotic Resistance in Mycobacterium Tuberculosis, *Mycobacterial Diseases*, 4.
- Deviernur, S. M., & Adnan, N., 2023, Analisis Survival: Hubungan Konversi Sputum dengan Keberhasilan Pengobatan Pasien Tuberkulosis Resistan Obat di Indonesia, *Jurnal Epidemiologi Kesehatan Indonesia*, 7(1).
- Dhestina, W., Santoso, P., & Sahiratmadja, E., 2022, Proportion of Extrapulmonary MDR-TB Confirmed by GeneXpert® in Dr. Hasan

- Sadikin General Hospital, West Java, Indonesia Year 2012–2021, *Indonesian Journal of Tropical and Infectious Disease*, 10(2), 113–122.
- Diel, R., Sotgiu, G., Andres, S., Hillemann, D., & Maurer, F. P., 2021, Cost of Multidrug Resistant Tuberculosis in Germany – An update, *International Journal of Infectious Diseases*, 103, 102–109.
- Dookie, N., Rambaran, S., Padayatchi, N., Mahomed, S., Naidoo, K., 2018, Evolution of Drug Resistance In *Mycobacterium Tuberculosis*: A Review on The Molecular Determinants of Resistance and Implications for Personalized Care, *Journal of Antimicrobial Chemotherapy*, 73(5), 1138–1151.
- Evans, D., Hirasen, K., Ramushu, C., Long, L., Sinanovic, E., Conradie, F., Howell, P., Padanilam, X., Ferreira, H., Variaiva, E., Rajaram, S., Gupta, A., Juneja, S., & Ndjeka, N., 2024, Patient and Provider Costs of the New BPaL Regimen for Drug-Resistant Tuberculosis Treatment in South Africa: A Cost-Effectiveness Analysis, *PLoS One*, 19(10).
- Fahlaifi, M., Usman, S., & Ismail, N., 2023, Determinan Faktor Terjadinya Multidrug Resistant pada Pengobatan TB Paru (MDR-TB) di Rumah Sakit Umum Daerah dr. Zainoel Abidin, *Sehat Rakyat: Jurnal Kesehatan Masyarakat*, 2, 33–42.
- Fekadu, G., Tolossa, T., Turi, E., Bekele, F., & Fetensa, G., 2022, Pretomanid development and its clinical roles in treating tuberculosis, *Journal of Global Antimicrobial Resistance*, 31, 175–184.
- Feuth, T., Patovirta, R. L., Grierson, S., Danilovits, M., Viikklepp, P., Aaltonen, H. K., Vauhkonen, M., Pehme, L., & Vasankari, T., 2021, Costs of Multidrug-Resistant TB Treatment in Finland and Estonia Affected by the 2019 WHO Guidelines, *International Journal of Tuberculosis and Lung Disease*, 25(7), 554–559.
- Fitriana, S. N., Zulkarnain, B. S., & Yulimanida, H., 2023, Analisis Efek Samping Kanamisin dan Kapreomisin terhadap Fungsi Ginjal pada Pasien TB RO di RSUD Dr. Soetomo, *Cendekia Journal of Pharmacy*, 7(1),
- George, C., Leslie, S. W., & Minter, D. A., 2023, *Hyperuricemia*, StatPearls Publishing, Treasure Island.
- Goulouze, S. C., Cohen, A. F., & Rissmann, R., 2015, Bedaquiline, *British Journal of Clinical Pharmacology*, 80(2), 182–184.
- Handari, R. D., & Ronoatmodjo, S., 2024, Prevalensi dan Faktor Risiko Kejadian Efek Samping Obat pada Pasien TB-MDR: Literature Review, *Media Publikasi Promosi Kesehatan Indonesia*, 7(3), 506–517.
- Heckroth, M., Luckett, R. T., Moser, C., Parajuli, D., & Abell, T. L., 2021, Nausea and Vomiting in 2021: A Comprehensive Update, *Journal of Clinical Gastroenterology*, 55(4), 279–299.

- Heemskerk, D., Caws, M., Marais, B., & Jeremy, F., 2015, *Tuberculosis in Adults and Children*, Springer, London.
- Hirpa, S., Medhin, G., Girma, B., Melese, M., Mekonen, A., Suarez, P., & Ameni, G., 2013, Determinants of Multidrug-Resistant Tuberculosis In Patients Who Underwent First-Line Treatment In Addis Ababa: A Case Control Study, *BMC Public Health*, 13, 782.
- Ifayani, O., Puspitasari, I. M., Insani, W. N., & Pradipta, I. S., 2023, Efek Samping Obat pada Pengobatan Tuberkulosis Resisten Obat Ganda, *Majalah Farmasi dan Farmakologi*, 27(1), 10–14.
- Intini, E., Kishore, G., Richeldi, L., & Udwadia, Z. F., 2019, Neuropsychiatric Reactions Induced by Cycloserine in The Treatment of Multidrug-Resistant Tuberculosis: What an Indian Female Patient Tells Us, *BMJ Case Reports*, 12(12).
- Iswari, A., Endarti, D., Trijayanti, C., Haris, R.N.H., & Imansari, A.N.R., 2020, Analisis Biaya Penyakit Tuberkulosis: Studi Kasus di Salah Satu Puskesmas dan Rumah Sakit di Yogyakarta, *Majalah Farmaseutik*, 16(2), 211-217.
- Jin, X., Chen, D., Wu, F., Zhang, L., Huang, Y., Lin, Z., Wang, X., Wang, R., Xu, L., & Chen, Y., 2020, Hydrogen Sulfide Protects Against Ammonia-Induced Neurotoxicity Through Activation of Nrf2/ARE Signaling in Astrocytic Model of Hepatic Encephalopathy, *Frontiers in Cellular Neuroscience*, 14.
- Kariuki, J., Kariuki, S., & Angel, P., 2023, The Role of Pyridoxine in the Prevention and Treatment of Neuropathy and Neurotoxicity Associated with Rifampicin-Resistant Tuberculosis Treatment Regimens: A Topic Review, *Journal of Tuberculosis Research*, 11, 33–48.
- Karnan, A., Jadhav, U., Ghewade, B., Ledwani, A., & Shivashankar, P., 2024, A Comprehensive Review on Long vs. Short Regimens in Multidrug-Resistant Tuberculosis (MDR-TB) Under Programmatic Management of Drug-Resistant Tuberculosis (PMDT), *Cureus*, 16(1).
- Kasron, Rahayu, Y. S. E., & Sobirin. (2020) Karakteristik Pasien TB-MDR di RSUD Cilacap Periode Januari - Desember 2017, *Media Ilmu Kesehatan*, 8(2):171–179.
- Kementerian Kesehatan RI, 2013, *Pedoman Penerapan Kajian Farmakoekonomi*, Jakarta.
- Kementerian Kesehatan RI, 2019, Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/755/2019, Departemen Kesehatan RI, Jakarta.
- Kementerian Kesehatan RI, 2020, *Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia*, Kementerian Kesehatan RI, Jakarta.

- Kementerian Kesehatan RI, 2023, *Buku Pegangan Operasional Pengobatan Tuberkulosis Resistan dengan Paduan BPAL/M*, Kementerian Kesehatan RI, Jakarta.
- Khasanah, H. R., Pudiarifanti, N., Baharyati, D., Meliyarta, E., & Inayah, A. N., 2024, Efek Samping Penggunaan Obat Anti Tuberkulosis di Puskesmas Kota Bengkulu Tahun 2024, *Jurnal Ilmiah Avicenna*, 19(3), 190–199.
- Kwon, Y. S., Choi, J. W., Lee, H. S., Kim, J. H., Kim, Y., & Lee, J. J., 2020, Effect of a Preoperative Proton Pump Inhibitor and Gastroesophageal Reflux Disease on Postoperative Nausea and Vomiting, *Journal of Clinical Medicine*, 9(3), 825.
- Laili, F., Octavia, D., & Muhtaromah, M., 2023, Hubungan Kepatuhan Pengobatan TB-RO terhadap Outcome Terapi Pasien Tuberkulosis di Rumah Sakit Muhammadiyah Lamongan, *Jurnal Sains dan Kesehatan*, 5, 659–665.
- Lan, X. H., Hu, Y., Cao, Y. J., Liu, P., Ren, Q. T., & Zhu, W. W., 2023, Linezolid induced hypoglycemia and anemia: A case report, *Clinical Case Reports*, 11.
- Laurent, S., 2017, Antihypertensive Drugs, *Pharmacological Research*, 124, 116–125.
- Lee, H.Y., Lee, J., Lee, Y.S., Kim, M.Y., Lee, H.K., Lee, Y.M., Shin, J.H., & Ko, Y., 2015, Drug-Resistance Pattern of Mycobacterium Tuberculosis Strains From Patients with Pulmonary and Extrapulmonary Tuberculosis During 2006 to 2013 in a Korean Tertiary Medical Center, *Korean Journal of Internal Medicine*, 30(3), 325–334.
- Liebenberg, D., Gordhan, B.G., Kana, & B.D., 2022, Drug Resistant Tuberculosis: Implications for Transmission, Diagnosis, and Disease Management, *Frontiers in Cellular and Infection Microbiology*, 12.
- Loi, M., Wang, J., Ong, C., & Lee, J. H., 2017, Nutritional Support of Critically Ill Adults and Children With Acute Respiratory Distress Syndrome: A Clinical Review, *Clinical Nutrition ESPEN*, 19, 1–8.
- Maulida, D. H., Dewi, I. M. W., Santoso, P., Cahyandi, A. I., Kusmawati, M., & Kulsum, I. D., 2024, Prevalensi dan Karakteristik Pasien Tuberkulosis Paru Resisten Obat (TB-RO) dengan Diabetes Melitus Tipe 2 di Klinik TB-RO Rumah Sakit Umum Pusat Dr. Hasan Sadikin, Bandung, *Jurnal Penyakit Dalam Indonesia*, 11(2), Artikel 6.
- Mereškevičienė, R., & Danila, E., 2025, The adverse effects of tuberculosis treatment: A comprehensive literature review, *Medicina*, 61(5), 911.
- Mizukawa, Y., Hirahara, K., Kano, Y., & Shiohara, T., 2018, Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms Severity Score: A Useful Tool for Assessing

- Disease Severity and Predicting Fatal Cytomegalovirus Disease, *J Allergy Clin Immunol Pract*, 11(10).
- Mondoni, M., Albrici, C., Terraneo, S., Puci, M., Maggioni, S., Ferranti, G., Henchi, S., Viganò, O., Santoro, A., Marchetti, G., Centanni, S., Dobler, C.C., & Sotgiu, G., 2025, Prevalence and Short-Term Outcomes of Acute Complications Of Tuberculosis: A Cross-Sectional, Monocentre, Italian study, *BMC Infectious Diseases*, 25, 564.
- Mulder, C., Rupert, S., Setiawan, E., Mambetova, E., Edo, P., Sugiharto, J., Useni, S., Malhotra, S., Cook-Scalise, S., Pambudi, I., Kadyrov, A., Lawanson, A., Van den Hof, S., Gebhard, A., Juneja, S., & Sohn, H., 2022, Budgetary Impact of Using BPaL for Treating Extensively Drug-Resistant Tuberculosis, *BMJ Glob Health*, 7(1).
- Murniati, M., Handayani, D., & Isbaniah, F., 2020, Two-years Biannual Evaluation of Drug-resistant Tuberculosis Patients Completing Their Treatment at Persahabatan General Hospital Jakarta, *Respiratory Science*, 1(1), 15–32.
- Nihlah, N.A., Almattin, B.N., & Wicaksono, I.A., 2024, Adverse events of bedaquiline drug use in the treatment of multidrug-resistant tuberculosis (MDR TB) patients: A review, *Pharmacology and Clinical Pharmacy Research*, 9(1).
- Nugraha, R.V., Yunivita, V., Santoso, P., Aarnoutse, R.E., & Ruslami, R., 2021, Clofazimine as a treatment for multidrug-resistant tuberculosis: A review, *Scientia Pharmaceutica*, 89(2).
- Nurfaujiah, A., Ferdian, F., & Andriyoko, B., 2023, Gambaran Efek Samping Panduan Standar Jangka Pendek dan Panjang pada Tuberkulosis Resisten Obat, *Indonesia Journal Chest*, 10(1).
- Papich, M. G., 2018, Fluoroquinolone Antimicrobial Drugs, *Veterian Key*.
- Pasipanodya, J. G., McIlleron, H., Burger, A., Wash, P. A., Smith, P., & Gumbo, T., 2013, Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes, *Journal of Infectious Diseases*, 208(9), 1464–1473.
- PERKENI, 2021, *Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia*, PB Perkeni, Jakarta.
- Prasad, R., Singh, A., & Gupta, N., 2021, Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis, *Annals of the National Academy of Medical Sciences*, 57, 16–35.
- Puspitaningrum, A.N., Vidiani, A. A. P. P., Girsang, V., & Adrianto, M., 2024, Cost of Illness pada Pasien Tuberkulosis Non-MDR, *Jurnal Farmasi dan Manajemen Kefarmasian (JFMK)*, 2, 1-7.
- Putra, O. N., Purnamasari, T., & Hamami, N. M., 2024, Pyrazinamide-induced

- Hyperuricemia in Pulmonary Tuberculosis Patients, *International Journal of Mycobacteriology*, 13(3), 282–287.
- Raikar, S.R., G S, Sneha, S., & Rajkumar, J., 2025, Cycloserine-induced psychosis: A case report, *Cureus*, 17(1).
- Rathod, K. B., Borkar, M. S., Lamb, A. R., Suryavanshi, S. L., Surwade, G. A., & Pandey, V. R., 2015, Adverse Events Among Patients of Multi Drug Resistant Tuberculosis Receiving Second Line Anti Tb Treatment, *International Journal of Scientific Reports*, 1(6), 253–257.
- Rizal, V., Rustam, E., & Anggrainy, F., 2021, Karakteristik Pasien Multidrug Resistant Tuberculosis yang Dirawat di Bangsal Paru Rsup Dr. M. Djamil Padang Periode 2018–2020, *Jurnal Farmasi Higea*, 13(2), 143.
- Rosdiana, D., Anggraini, D., Yovi, I., & Tasril, M., 2020, Profil and Evaluation of Resistant Tuberculosis Drug's Side Effect in Diabetes and Non Diabetes Mellitus Patient at RSUD Arifin Achmad, *Jurnal Respirologi Indonesia*, 40(3), 156–162.
- Safana, L. N., Hidayati, S., & Palupi, J., 2024, Profile of Drug Use in Outpatients with Multidrug Resistant Tuberculosis (MDR-TB) at RSD dr. Soebandi Jember, *Indonesian Pharmacopeia Journal*, 1(2), 96–108.
- Sari, I. D., Herman, M. J., Susyanty, A. L., & Su'udi, A., 2017, Analisis Biaya Tuberkulosis Paru Kategori Satu Pasien Dewasa di Rumah Sakit di DKI Jakarta, *Jurnal Kefarmasian Indonesia*, 8(1), 44-54.
- Seddon, J. A., Godfrey-Faussett, P., Hesselning, A. C., Gie, R. P., Beyers, N., & Schaaf, H. S., 2012, Management of Children Exposed to Multidrug-resistant Mycobacterium Tuberculosis, *The Lancet Infectious Diseases*, 12(6), 469-479.
- Setiani, N., Fajarini, H., & Balfas, R. F., 2023, Pola Penggunaan Obat Tuberkulosis Resisten Obat pada Pasien Rawat Inap di Rumah Sakit Umum Daerah Brebes, *MOTEKAR: Jurnal Multidisiplin Teknologi dan Arsitektur*, 1(2), 108–115.
- Setiawan, M., Yustikasari, Y. G., Surianata, R. W., Permana R. A., Hakiki, N., & Ornadi, A. B., 2024, Profile of Drug-Resistant Tuberculosis Patients at the Haji Regional Hospital, East Java Province in 2019–2022, *Jurnal Saintika Medika*, 20(1).
- Seung, K. J., Keshavjee, S., & Rich, M. L., 2015, Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis, *Cold Spring Harbor Perspectives in Medicine*, 5(9).
- Siahaan, A. G. H., Polii, E. B. I., & Ongkowijaya, J., 2016, Profil Pasien Tuberkulosis dengan Multi Drug Resistance (MDR) di RSUP Prof. Dr. R. D. Kandou Periode Agustus 2015 - Agustus 2016, *Jurnal e-Clinic (eCl)*, 4(2), Juli–Desember.

- Sirait, N., Parwati, I., Susana, N., & Suraya, N., 2013, Validitas Pemeriksaan Metode Polymerase Chain Reaction Genexpert MTB/RIF, *Majalah Kesehatan Bandung*, 45(4).
- Soedarsono, S., Mertaniasih, N. M., Hasan, H., Kusmiati, T., Permatasari, A., Kusumaningrum, D., Wijaksono, W., 2022, Line Probe Assay Test in New Cases of Tuberculosis with Rifampicin Resistance Not Detected by Xpert MTB/RIF, *International Journal of Mycobacteriology*, 11, 429.
- Subchan, D. S., & Kunoli, F. H. Y., 2022, Gambaran Kejadian Efek Samping Obat (ESO) dengan Kejadian Putus Obat pada Pasien TB Paru di RSUD Luwuk, *Poltekita: Jurnal Ilmu Kesehatan*, 16(3), 345–351.
- Suryaningrat, D., & Fitrasari, E., 2021, Gambaran Penggunaan Obat dan Biaya Pengobatan Penyakit TBC Paru Pasien BPJS Rawat Inap di RSUD Dokter Soedarso Bulan September – November Tahun 2018, *Jurnal Komunitas Farmasi Nasional*, 1(1), 8–13.
- Tao, N., Li, Y., Song, W., Liu, J. Y., Zhang, Q. Y., Xu, T. T., Li, S. J., An, Q. Q., Liu, S. Q., & Li, H. C., 2021, Risk Factors for Drug-Resistant Tuberculosis, the Association Between Comorbidity Status and Drug-Resistant Patterns: a Retrospective Study of Previously Treated Pulmonary Tuberculosis in Shandong, China, During 2004–2019, *BMJ Open*, 11(6).
- Thee, S., Garcia-Prats, A.J., Donald, P.R., Hesselning, A.C., & Schaaf, H.S., 2016, A review of the use of ethionamide and prothionamide in childhood tuberculosis, *Tuberculosis (Edinburgh)*, 96(1), 126–136.
- Tiemersma, E.W., van der Werf, M.J., Borgdorff, M.W., Williams, B.G., & Nagelkerke, N.J., 2011, Natural History of Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients: A Systematic Review, *PLoS One*, 6(4).
- Tobin, E.H., & Tristram, D., 2024, *Tuberculosis*, StatPearls Publishing, Treasure Island.
- Tonin, F. S., Aznar-Lou, I., Pontinha, V. M., Pontarolo, R., & Fernandez-Llimos, F., 2021, Principles of Pharmacoeconomic Analysis: The Case of Pharmacist-Led Interventions, *Pharmacy Practice (Granada)*, 19(1).
- Wahidah, I., Arwi, K. M., Norcahyanti, I., Rachmawati, E., Dewi, I. P., Aryani, D. E., & Machlaurin, A., 2024, Determinan Pola Resistensi Pasien Multi-Drug Resistant Tuberculosis (MDR-TB): Studi Multi-Center di Jember, Indonesia. *Indonesian Journal of Pharmaceutical Education*, 4.
- Wells, B.G., DiPiro, J.T., Schwinghammer, T.L., & DiPiro, C.V., 2017, *Pharmacotherapy Handbook*, Edisi ke-10., McGraw-Hill, New York.
- WHO, 2011, *Guidelines for the programmatic management of drug-resistant tuberculosis – 2011 update*, WHO, Geneva.

- WHO, 2016, *WHO treatment guidelines for drug-resistant tuberculosis, 2016 update*, WHO, Geneva.
- WHO, 2018, *Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB)*, WHO, Geneva.
- WHO, 2020, *WHO consolidated guidelines on tuberculosis: Module 4: Treatment – Drug-resistant tuberculosis treatment* WHO, Geneva.
- WHO, 2022, *WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment - Drug-resistant Tuberculosis Treatment*, WHO, Geneva.
- WHO, 2023, *Global Tuberculosis Report 2023*, WHO, Geneva.
- WHO, 2024, *Tuberculosis: Multidrug-resistant (MDR-TB) or Rifampicin-resistant TB (RR-TB)*, [https://www.who.int/news-room/questions-and-answers/item/tuberculosis-multidrug-resistant-tuberculosis-\(mdr-tb\)](https://www.who.int/news-room/questions-and-answers/item/tuberculosis-multidrug-resistant-tuberculosis-(mdr-tb)), 20 Mei 2024.
- Wibowo, A., Burhan, E., & Putra, A. C., 2021, Pola Resistansi Kuman Tuberkulosis dan Regimen Pengobatan pada Pasien Tuberkulosis Resisten Obat di Rumah Sakit Pusat Rujukan Respirasi Nasional Persahabatan Jakarta, *Jurnal Kedokteran Universitas Lampung*, 5(1).
- Yadav, S., 2022, Cycloserine-Induced Insomnia and Psychosis in Multidrug-Resistant Pulmonary Tuberculosis – A Case Report, *Cureus*, 14(12).
- Yamaguti, V., Rijo, R., Crepaldi, N., Ruffino-Netto, A., Carvalho, I., & Alves, D., 2018, Charlson Comorbidities Index Importance Evaluation as a Predictor to Tuberculosis Treatments Outcome in The State of São Paulo, Brazil, *Procedia Computer Science*, 138, 258–263.
- Yamanaka, T., Castro, M.C., Ferrer, J.P., Solon, J.A., Cox, S.E., Laurence, Y.V., & Vassall, A., 2024, Costs incurred by people with co-morbid tuberculosis and diabetes and their households in the Philippines, *PLoS ONE*, 19(1).
- Yang, F., Yu, H., Kantipudi, K., Karki, M., Kassim, Y.M., Rosenthal, A., Hurt, D.E., Yaniv, Z., & Jaeger, S., 2022, Differentiating between Drug-Sensitive and Drug-Resistant Tuberculosis with Machine Learning for Clinical and Radiological Features, *Quantitative Imaging in Medicine and Surgery*, 12(1): 675-687.
- Yuan, Y., Li, J., Chen, Y., Cai, Q., Xu, Y., Lin, L., Lang, Y., Guo, S., Zhang, R., & Cai, X., 2022, Mechanism Underlying Linezolid-Induced Peripheral Neuropathy in Multidrug-Resistant Tuberculosis, *Frontiers in Pharmacology*, 13.
- Zhou, K., Qin, Q., & Lu, J., 2025, Pathophysiological Mechanisms Of Ards: A Narrative Review from Molecular to Organ-Level Perspectives, *Respiratory Research*, 26, 54.